A phase I study of zoledronic acid (Zometa) with cyclophosphamide in children with recurrent or refractory neuroblastoma and cortical bone involvement (NANT 2004-01).
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Zoledronic acid (Primary) ; Cyclophosphamide
- Indications Neuroblastoma
- Focus Adverse reactions
- 14 May 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 14 May 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 14 May 2012 Actual patient number 21 added as reported by ClinicalTrials.gov.